Immunome Inc

Immunome, Inc. is a biotechnology company focused on the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. Its clinical-stage assets include Varegacestat, a gamma secretase inhibitor in Phase 3 trials for desmoid tumors, and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC) in Phase 1 trials. The company also has preclinical assets such as IM-3050, a fibroblast activation protein targeted radioligand therapy, and solid tumor ADC candidates IM-1617, IM-1340, and IM-1335. Incorporated in 2006, Immunome is based in Bothell, Washington.

IMNM▲2

Immunome Director Sells $2.4 Million in Shares Day Before FDA Accepts Lead Drug Application

Immunome director Isaac Barchas sold 100,000 shares for approximately $2.4 million on July 7, 2026, one day before the FDA accepted the company's lead drug application for review. The sale was executed under a pre-established Rule 10b5-1 trading plan through AMBHMC II LLC, leaving Barchas with 103,259 directly held shares and 108,504 indirectly held shares. The transaction occurred as Immunome's stock had returned 181% over the prior year, with shares priced at $23.90 at the July 6 close. The FDA accepted the application for varegacestat, an oral desmoid tumor therapy, and set a decision date of April 28, 2027, following Phase 3 data showing an 84% lower risk of progression. Immunome, a clinical-stage oncology company with a $2.3 billion market capitalization, reported trailing-twelve-month revenue of $4.0 million and a net loss of $224.6 million, while holding $582.7 million in cash as of March 31, 2026.

IMNM ▲

The Motley Fool·68dRead more →